CD19 and B-cell non-Hodgkin lymphoma: Other CAR constructs include bispecific anti-CD19/CD20 CAR T cells (LV20.19) showed an ORR of 100% at 92 days with CR of 92% in phase-1 clinical trial of B cell lymphoma patients, including seven heavily pretreated MCL cases (NCT03019055) [181].